2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Cisplatin
29
Magnetic Resonance Spectroscopy
16
Specimen Handling
13
Radiotherapy
12
pembrolizumab
11
Radiotherapy, Intensity-Modulated
11
Cetuximab
11
Surgical Procedures, Operative
9
Paclitaxel
9
Fluorouracil
9
Docetaxel
9
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Radiation
6
Carboplatin
6
Taxes
5
Biopsy
5
toripalimab
4
X-Rays
4
Surveys and Questionnaires
4
Fluorodeoxyglucose F18
4
Chemoradiotherapy
4
Celecoxib
4
(225)Ac-DOTA-c(RGDyK)
4
Immunohistochemistry
3
Counseling
3
130-nm albumin-bound paclitaxel
3
motexafin gadolinium
2
ipatasertib
2
camrelizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypopharyngeal Neoplasms
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn